Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In two patients (one with transfusion-dependent beta-thalassemia and one with sickle cell disease) treated with autologous CRISPR-Cas9-edited…
Vertex agreed to pay CRISPR Therapeutics $900 million upfront and an additional $200 million upon first regulatory approval to take a larger share of…
The U.S. Food and Drug Administration today approved Casgevy (exagamglogene autotemcel) for the treatment of transfusion-dependent beta-thalassemia in patients…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Vertex and CRISPR amended their CTX001 collaboration so Vertex leads global development, manufacturing and commercialization with a 60/40 profit/cost split (Vertex 60%). CRISPR received $900M upfront and is eligible for $200M upon first regulatory approval, increasing Vertex's program economics by 10 percentage points.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG (this deal) | 2021 | $1.1B | — |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
← Browse all deals · How we score deals
More: 2021 deals · Vertex Pharmaceuticals Incorporated deals · Hematology deals